The development and therapeutic potential of protein kinase inhibitors.
A number of small cell-permeant protein kinase inhibitors have been developed that have the potential for treating a variety of diseases. The basis for the specificity of several of these drugs has been elucidated and a number are undergoing human clinical trials.
MRC Protein Phosphorylation Unit, Department of Biochemistry, MSI/WTB Complex, Dow Street, University of Dundee, Dundee, DD1 5EH, Scotland, UK. pcohen@bad.dundee.ac.uk
P
P
Cohen
D015195:Drug Design; D004791:Enzyme Inhibitors / Q000138:chemical synthesis* / Q000378:metabolism / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D007166:Immunosuppressive Agents / Q000138:chemical synthesis / Q000378:metabolism / Q000627:therapeutic use; D007249:Inflammation / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy; D010766:Phosphorylation; D047428:Protein Kinase Inhibitors; D011494:Protein Kinases / Q000378:metabolism; D013379:Substrate Specificity
D004791:Enzyme Inhibitors; D007166:Immunosuppressive Agents; D047428:Protein Kinase Inhibitors; D011494:Protein Kinases